The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd, known as Biovac or The Biovac Institute, is a Cape Town-based biopharmaceutical company founded in 2003 as a public-private partnership with the South African government. It focuses on developing and manufacturing vaccines to enhance Africa's self-reliance in vaccine production and supply.
Biovac supplies approximately 80% of South Africa's routine pediatric vaccines and has delivered over 450 million doses across southern Africa since inception. Its cGMP-compliant facilities in Cape Town support end-to-end processes including bacterial fermentation, purification, formulation, vial and syringe filling, and quality control testing. Key products include hexavalent and pneumococcal conjugate vaccines, produced in partnership with Sanofi Pasteur and Pfizer.
The company is expanding with Africa's first end-to-end multi-vaccine facility, backed by EIB, IFC, and EU funding, to produce oral cholera, polio, pneumococcal, and meningitis vaccines by 2028, targeting 30-40 million doses annually for regional needs via UNICEF and Gavi.
To provide comprehensive coverage, we aggregate data and news under the name Biovac, encompassing the following company names, divisions, and related entities:
The Biovac Institute.
This list encompasses current and former names, alternate names, and key divisions associated with Biovac, ensuring you can easily find all relevant information under a single, unified profile.
